The July Brand Monitor by Pharmarack shows a healthy top-20 portfolio overall, with growth concentrated in several large brands and clear market-share gains. The standout is Mounjaro, while Mixtard and Monocef—
Key observations
1. Mounjaro is the exceptional growth story.
Mounjaro ranks #1 at 109.8 value, growing 157%, versus the anti-diabetic super-group growth of only 18%. Its Evolution Index (EI) of 218% and incremental gain of 67.1 are by far the strongest in the table. This suggests substantial share capture rather than simply benefiting from category growth.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
